Chipscreen Biosciences, Ltd.
Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.
Small Cell Lung Cancer
Chiauranib
Not Applicable
Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment. Chiauranib is a novel orally active multi-target inhibitor that simultaneously inhibits the angiogenesis-related kinases (VEGFR2, VEGFR1, VEGFR3, PDGFRa and c-Kit), mitosis-related kinase Aurora B and chronic inflammationrelated kinase CSF-1R in a high potency manner with the IC50 at a single-digit nanomolar range. In particular, Chiauranib showed very high selectivity in the kinase inhibition profile with little activity on off-target non-receptor kinases, proteins, GPCR and ion channels, indicative of a better drug safety profile in terms of clinical relevance. This trial is a material balance study of [14C]Chiauranib in participants with small cell lung cancer, with the goal of learning more about the drug's absorption, metabolism, and excretion in the human body, as well as monitoring the subjects' safety after treatment. Chiauranib's scientific foundation for future progress.}}
Study Type : | Interventional |
Estimated Enrollment : | 6 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | Absorption, Metabolism and Excretion of [14C]Chiauranib in Patients With Small Cell Lung Cancer |
Actual Study Start Date : | July 20, 2022 |
Estimated Primary Completion Date : | November 30, 2023 |
Estimated Study Completion Date : | December 30, 2023 |
Arm | Intervention/treatment |
---|---|
Other: Chiauranib Take 50 mg ChiauranibCioroni capsules orally on an empty stomach once a day, every day; except on the eighth day 8, when you start taking Cioroni capsules liquid, take a single oral dose of ~50 mg/about 100 Ci of [14C]Chiauranib suspensionCioroni solution once on an empty stomach. |
Drug: Chiauranib |
Ages Eligible for Study: | 18 Years to 75 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
The First Affiliated Hospital of Suzhou University
Suzhou, Jiangsu, China, 21500